MDS Pharma Services Adopts Innovative Technology for Bioanalysis
02 Juni 2008 - 3:00PM
PR Newswire (US)
Electrochemiluminescent assay instruments offer increased
sensitivity and productivity KING OF PRUSSIA, PA, June 2
/PRNewswire-FirstCall/ -- MDS Pharma Services, a leading provider
of innovative drug discovery and development solutions, now offers
its bioanalysis clients the benefits of electrochemiluminescent
assay (ECLA) testing, with the recent installation and validation
of two state-of-the-art instruments at its laboratory in Montreal.
In many situations, ECLA test methodology provides greater
sensitivity and flexibility than standard radioimmunoassays or
ELISA techniques for quantitative pharmacokinetic and
immunogenicity testing of biological samples from clinical research
participants. These advantages are particularly important in
research involving biologics such as monoclonal antibodies because
traditional methodologies may not be capable of detecting anti-drug
antibodies in the presence of circulating drug. Biologic drugs are
made using living cells rather than chemicals and therefore have
the potential to trigger a potentially harmful immune response.
"With the growing focus on biologic drugs, including biologic
generics, the need to detect immune responses during clinical
research becomes increasingly important," said MDS Pharma Services
President David Spaight. "That's why MDS Pharma Services has added
ECLA testing to our bioanalytical testing repertoire of ligand
binding and cell-based assays." MDS Pharma Services is developing
ECLA assays for bone and metabolic biomarkers to leverage the
instruments' multiplexing capabilities, which allow for measurement
of multiple analytes or markers in a single test sample. This
multiplexing ability offers clients increased productivity in
keeping with MDS Pharma Services' brand promise to deliver
high-quality results on time. To accelerate client access to the
benefits of ECLA methodology, MDS Pharma Services fast-tracked the
validation of the two instruments and associated software,
redeploying resources to complete the validation process. The
instruments and software meet all applicable regulatory
requirements, including 21 CFR Part 11. About MDS Pharma Services
MDS Pharma Services is committed to delivering quality service
on-time. We offer a full spectrum of resources to meet the drug
discovery and development needs of the pharmaceutical and
biotechnology industries. With numerous facilities strategically
located around the world, we apply advanced scientific and
technological expertise throughout the drug discovery and
development process - from lead optimization, pre-IND research,
early clinical research (bioequivalence, phases I-IIa) and
bioanalysis through to global clinical development (phases IIb-IV),
central lab and centralized cardiac services. For more information,
visit our website at http://www.mdsps.com/. MDS Pharma Services is
a business unit of MDS Inc. (TSX: MDS; NYSE: MDZ), a global life
sciences company that provides market-leading products and services
that our customers need for the development of drugs and diagnosis
and treatment of disease. We are a leading global provider of
pharmaceutical contract research, medical isotopes for molecular
imaging, radiotherapeutics, and analytical instruments. MDS has
more than 5,500 highly skilled people in 28 countries. Find out
more at http://www.mdsinc.com/ or by calling 1-888-MDS-7222, 24
hours a day. DATASOURCE: MDS Pharma Services CONTACT: For
Investors, Kim Lee, (416) 213-4721, ; For Media, Charlene McGrady,
(610) 239-7900 ext. 231,
Copyright